278 related articles for article (PubMed ID: 20045317)
1. Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.
Aparoy P; Kumar Reddy K; Kalangi SK; Chandramohan Reddy T; Reddanna P
Bioorg Med Chem Lett; 2010 Feb; 20(3):1013-8. PubMed ID: 20045317
[TBL] [Abstract][Full Text] [Related]
2. A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it.
Wang HY; Li LL; Cao ZX; Luo SD; Wei YQ; Yang SY
Chem Biol Drug Des; 2009 Jan; 73(1):115-26. PubMed ID: 19152640
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors.
Wang HY; Cao ZX; Li LL; Jiang PD; Zhao YL; Luo SD; Yang L; Wei YQ; Yang SY
Bioorg Med Chem Lett; 2008 Sep; 18(18):4972-7. PubMed ID: 18762425
[TBL] [Abstract][Full Text] [Related]
4. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.
Sakkiah S; Thangapandian S; John S; Kwon YJ; Lee KW
Eur J Med Chem; 2010 Jun; 45(6):2132-40. PubMed ID: 20206418
[TBL] [Abstract][Full Text] [Related]
5. Farnesyltransferase pharmacophore model derived from diverse classes of inhibitors.
Lu A; Zhang J; Yin X; Luo X; Jiang H
Bioorg Med Chem Lett; 2007 Jan; 17(1):243-9. PubMed ID: 17049856
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors.
Saxena S; Chaudhaery SS; Varshney K; Saxena AK
SAR QSAR Environ Res; 2010 Jul; 21(5-6):445-62. PubMed ID: 20818581
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2.
Xie QQ; Xie HZ; Ren JX; Li LL; Yang SY
J Mol Graph Model; 2009 Feb; 27(6):751-8. PubMed ID: 19138543
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
Rao PN; Chen QH; Knaus EE
J Med Chem; 2006 Mar; 49(5):1668-83. PubMed ID: 16509583
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors.
Shih KC; Shiau CW; Chen TS; Ko CH; Lin CL; Lin CY; Hwang CS; Tang CY; Chen WR; Huang JW
Bioorg Med Chem Lett; 2011 Aug; 21(15):4490-7. PubMed ID: 21724393
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel acyl coenzyme a: cholesterol acyltransferase inhibitors: pharmacophore-based virtual screening, synthesis and pharmacology.
Chhabria MT; Brahmkshatriya PS; Mahajan BM; Darji UB; Shah GB
Chem Biol Drug Des; 2012 Jul; 80(1):106-13. PubMed ID: 22429570
[TBL] [Abstract][Full Text] [Related]
12. Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification.
Krovat EM; Langer T
J Med Chem; 2003 Feb; 46(5):716-26. PubMed ID: 12593652
[TBL] [Abstract][Full Text] [Related]
13. Structural insights into human 5-lipoxygenase inhibition: combined ligand-based and target-based approach.
Charlier C; Hénichart JP; Durant F; Wouters J
J Med Chem; 2006 Jan; 49(1):186-95. PubMed ID: 16392803
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore modeling and virtual screening studies to design some potential histone deacetylase inhibitors as new leads.
Vadivelan S; Sinha BN; Rambabu G; Boppana K; Jagarlapudi SA
J Mol Graph Model; 2008 Feb; 26(6):935-46. PubMed ID: 17707666
[TBL] [Abstract][Full Text] [Related]
15. A common feature-based 3D-pharmacophore model generation and virtual screening: identification of potential PfDHFR inhibitors.
Adane L; Bharatam PV; Sharma V
J Enzyme Inhib Med Chem; 2010 Oct; 25(5):635-45. PubMed ID: 19995305
[TBL] [Abstract][Full Text] [Related]
16. Discovery of dual binding site acetylcholinesterase inhibitors identified by pharmacophore modeling and sequential virtual screening techniques.
Gupta S; Fallarero A; Järvinen P; Karlsson D; Johnson MS; Vuorela PM; Mohan CG
Bioorg Med Chem Lett; 2011 Feb; 21(4):1105-12. PubMed ID: 21273074
[TBL] [Abstract][Full Text] [Related]
17. Virtual screening of cathepsin k inhibitors using docking and pharmacophore models.
Ravikumar M; Pavan S; Bairy S; Pramod AB; Sumakanth M; Kishore M; Sumithra T
Chem Biol Drug Des; 2008 Jul; 72(1):79-90. PubMed ID: 18498326
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore identification and virtual screening for methionyl-tRNA synthetase inhibitors.
Bharatham N; Bharatham K; Lee KW
J Mol Graph Model; 2007 Mar; 25(6):813-23. PubMed ID: 16996282
[TBL] [Abstract][Full Text] [Related]
19. Pharmacophore identification, docking and "in silico" screening for novel CDK1 inhibitors.
Dong X; Yan J; Du L; Wu P; Huang S; Liu T; Hu Y
J Mol Graph Model; 2012 Jul; 37():77-86. PubMed ID: 22622012
[TBL] [Abstract][Full Text] [Related]
20. Pharmacophore modelling and virtual screening for identification of new Aurora-A kinase inhibitors.
Deng XQ; Wang HY; Zhao YL; Xiang ML; Jiang PD; Cao ZX; Zheng YZ; Luo SD; Yu LT; Wei YQ; Yang SY
Chem Biol Drug Des; 2008 Jun; 71(6):533-9. PubMed ID: 18410307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
